Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Mast Group Launches New ESPLINE SARS-CoV-2 Lateral Flow Antigen Test

By LabMedica International staff writers
Posted on 26 Nov 2020
Mast Group Ltd. More...
(Liverpool, UK) has launched the new ESPLINE SARS-CoV-2 lateral flow antigen test for the detection of COVID-19.

The ESPLINE SARS-CoV-2 is an immunochromographic assay for the detection of SARS-CoV-2 antigen directly from nasopharyngeal swab. The lateral flow test is to be used as an aid in the diagnosis of SARS-CoV-2 infection. ESPLINE SARS-CoV-2 is a cassette-style assay using a simple procedure without any special instruments. As a feature, the test kit utilizes several kinds of antibodies to capture protein insideSARS-CoV-2 and coloring method based on enzyme reaction to detect the antigen-antibody complex.

The test kit shows test result within 30 minutes after the reaction begins (positive results: 10-30 minutes, negative results: 30 minutes). The ESPLINE SARS-CoV-2 lateral flow antigen test has a sensitivity of 80% and specificity of 100%.

Related Links:
Mast Group Ltd.


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.